VNDA Stock Forecast: Vanda Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$3.44
−6.27% on the day

The median 12-month analyst price target for Vanda Pharmaceuticals, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 72 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$208.6M
Ticker Nerd rank
72/ 100
Median analyst target
$11
Analysts covering
5
Revenue$50.5M−3.9% y/y
Operating income−$63.8M
Net income−$62.5M
Free cash flow−$31.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.8%
1M
−17.5%
YTD
−61.0%
1Y
−28.9%
From 52W high
−64.0%
From 52W low
0.0%
$3.44
$9.56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Vanda Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
72/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Volatility
80
Revisions
75
Quality
58
Value
57
Growth
43
Momentum
42
Issuance
30

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (30): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VNDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VNDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26VNDAHigh $20Median $11Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4
Buy
1
Hold
0
Sell
$5
Low
$11
Median
$20
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
5 Oct 2026HC Wainwright & Co.ReiteratesBuy$20
23 Sept 2026OppenheimerInitiatesOutperform$10
10 Aug 2026B. Riley SecuritiesReiteratesBuy$17 → $12
10 Aug 2026HC Wainwright & Co.MaintainsBuy$21 → $20
11 May 2026HC Wainwright & Co.MaintainsBuy$24 → $21
5 Mar 2026Truist SecuritiesInitiatesBuy—
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
5 Jan 2026HC Wainwright & Co.MaintainsBuy—
31 Dec 2025B. Riley SecuritiesMaintainsBuy—
31 Dec 2025JefferiesMaintainsHold—
19 Nov 2025HC Wainwright & Co.ReiteratesBuy—
5 Nov 2025B. Riley SecuritiesInitiatesBuy—
30 Oct 2025Cantor FitzgeraldMaintainsOverweight—
21 Aug 2025HC Wainwright & Co.ReiteratesBuy—
14 May 2025Cantor FitzgeraldAssumesOverweight$13
7 May 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
18 Feb 2025HC Wainwright & Co.MaintainsBuy—
4 Feb 2025HC Wainwright & Co.ReiteratesBuy—
28 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VNDA.

Market Radar

This page is one stock. Monday covers all of them.

VNDA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VNDA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Vanda Pharmaceuticals, Inc. returned −28.9% against +6.9% for the S&P 500, dividends included.

VNDA vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180200Jan 26Apr 26Jul 26Oct 26VNDAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VNDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.9×

Cheaper than 68% of US stocks

Price / book
1.0×

Cheaper than 69% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
93.0%

Higher than 97% of US stocks

Operating margin
−77.6%

Higher than 16% of US stocks

Net margin
—
Returns & dividend
Return on equity
−82.5%

Higher than 16% of US stocks

Return on assets
−22.6%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vanda Pharmaceuticals, Inc. has a market value of $208.6M and an enterprise value of $89.8M.

  • Revenue in the twelve months to 30 June 2026: $215.7M. The latest quarter shrank 3.9% year on year.

  • Net income over the same four quarters: −$274.9M, a −127.4% net margin.

  • Diluted earnings per share, trailing twelve months: −$4.63.

  • Free cash flow in the twelve months to 30 June 2026: −$153.0M.

  • Shares outstanding: 60.5M.

  • forward P/E: 17.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Vanda Pharmaceuticals, Inc. employs 533 people — $405K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

VNDA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VNDAVanda Pharmaceuticals, Inc.$208.6M72
FTHFaeth Therapeutics, Inc.$203.1M26
DTILPrecision BioSciences, Inc.$204.3M81
CABACabaletta Bio, Inc.$201.9M28
ALLOAllogene Therapeutics, Inc.$207.9M45
DRUGBright Minds Biosciences, Inc.$198.5M17
ACIUAC Immune SA$198.5M66

Take a look at VNDA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Vanda Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about VNDA

What is the VNDA stock price forecast for 2026-2027?

The median 12-month analyst price target for Vanda Pharmaceuticals, Inc. is $11, with estimates ranging from $4.5 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VNDA stock a buy right now?

Of the 5 analysts covering Vanda Pharmaceuticals, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vanda Pharmaceuticals, Inc. 72 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VNDA?

As at 21 Nov 2026, Vanda Pharmaceuticals, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will VNDA stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $11, and Ticker Nerd's factor model ranks Vanda Pharmaceuticals, Inc. 72 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VNDA stock forecast for 2030?

No analyst covering Vanda Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VNDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.5 to $20 over the next 12 months.

How has VNDA stock performed over the past year?

Vanda Pharmaceuticals, Inc. returned -28.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vanda Pharmaceuticals, Inc. do?

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its current portfolio centers on treatments for sleep-wake disorders, schizophrenia, and other central nervous system conditions, supported by a selective pipeline that includes additional clinical and preclinical programs.

Company

About Vanda Pharmaceuticals, Inc.

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its current portfolio centers on treatments for sleep-wake disorders, schizophrenia, and other central nervous system conditions, supported by a selective pipeline that includes additional clinical and preclinical programs. The company’s marketed products include HETLIOZ and Fanapt, while PONVORY adds a presence in immune-related therapeutics. Vanda also works on specialty medicines for rare diseases and other targeted indications, using genetics and genomics to guide drug discovery and clinical development. With a concentrated product mix and a research-driven model, Vanda Pharmaceuticals Inc. plays a specialized role in the biopharmaceutical market by addressing niche patient populations where treatment options may be limited.

CEO Dr. Mihael H. Polymeropoulos M.D. · 533 employees · United States · https://www.vandapharma.com